Innova Captab Ltd

Innova Captab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Innova Captab Ltd

₹ 911 1.17%
22 Aug - close price
innovacaptab.com BSE: 544067 NSE: INNOVACAP
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain

Website BSE NSE
  • Market Cap ₹ 5,215 Cr.
  • Current Price ₹ 911
  • High / Low ₹ 1,260 / 648
  • Stock P/E 59.6
  • Book Value ₹ 142
  • Dividend Yield 0.00 %
  • ROCE 11.6 %
  • ROE 11.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
225 228 217 219 212 236 198 227 240 249 243 287
196 200 195 191 185 206 175 198 207 216 214 252
Operating Profit 29 29 22 28 26 31 23 28 33 32 28 35
OPM % 13% 13% 10% 13% 12% 13% 12% 13% 14% 13% 12% 12%
2 3 2 1 2 2 6 5 4 3 4 4
Interest 5 5 5 4 5 4 0 0 0 0 2 3
Depreciation 3 2 3 3 3 3 3 3 3 3 8 9
Profit before tax 23 24 16 21 20 26 26 30 34 33 23 27
Tax % 25% 32% 17% 29% 29% 27% 25% 25% 25% 26% 25% 26%
17 16 14 15 14 19 20 22 26 24 17 20
EPS in Rs 3.56 3.36 2.81 3.19 3.01 3.26 3.45 3.90 4.48 4.26 2.99 3.55
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
373 411 785 859 865 958 1,018
322 356 687 760 755 836 890
Operating Profit 51 54 99 99 110 122 129
OPM % 14% 13% 13% 11% 13% 13% 13%
1 1 3 9 9 17 16
Interest 5 4 5 18 14 2 5
Depreciation 10 6 7 11 11 17 23
Profit before tax 38 46 89 78 94 120 117
Tax % 26% 26% 25% 26% 27% 25%
28 34 66 58 68 89 87
EPS in Rs 232.42 287.50 551.50 11.99 11.91 15.63 15.28
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 21%
3 Years: 7%
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: 26%
3 Years: 11%
TTM: 16%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 32%
Return on Equity
10 Years: %
5 Years: 17%
3 Years: 14%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 12 12 48 57 57
Reserves 98 133 199 220 666 756
54 45 176 237 244 329
81 178 157 173 187 223
Total Liabilities 245 368 544 678 1,155 1,365
73 79 161 161 164 637
CWIP 0 7 0 22 339 21
Investments 0 0 60 60 60 60
172 282 322 435 593 647
Total Assets 245 368 544 678 1,155 1,365

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
31 42 58 39 112 20
-6 -20 -188 -88 -472 -100
-23 -19 125 51 368 84
Net Cash Flow 1 3 -5 3 8 4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 85 123 81 98 92 95
Inventory Days 84 107 63 67 68 94
Days Payable 92 132 84 102 111 119
Cash Conversion Cycle 77 99 60 63 49 70
Working Capital Days 45 39 23 44 58 65
ROCE % 28% 33% 21% 15% 12%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
50.90% 50.90% 50.90% 50.90% 50.90% 50.90% 50.90%
3.57% 1.94% 1.19% 1.01% 0.74% 0.35% 0.23%
10.31% 20.78% 21.24% 20.61% 19.96% 19.77% 19.67%
35.22% 26.39% 26.67% 27.48% 28.41% 29.00% 29.20%
No. of Shareholders 1,39,11739,39635,11532,25436,69239,99641,014

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls